Navigation Links
Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
Date:10/24/2007

this study had enrolled 26 patients with a variety of advanced solid tumors. 11 of 21 patients assessable for tumor response receiving doses of XL647 ranging from 75 to 300 mg achieved stable disease for at least three months. The XL647 exposure with daily dosing at the maximum tolerated dose (MTD) (300 mg) in this study was approximately twofold higher over a 28-day cycle compared to the exposure observed previously at the MTD (350 mg) for the intermittent dosing regimen. XL647 was generally well tolerated and related Grade 3 adverse events were infrequent. No Grade 3 or greater skin rash was reported in this study. Pharmacodynamic analyses were conducted in plasma samples and eyebrow hair follicles. Biomarker changes consistent with EGFR inhibition were observed in eyebrow hair follicles following XL647 treatment.

"The phase 2 data continue to show encouraging anti-tumor activity for XL647 given on an intermittent schedule in previously untreated clinically selected NSCLC patients. Additionally, phase 1 data suggest that XL647 dosed daily at 300 mg is well tolerated and provides approximately twofold higher drug exposure over a 28-day cycle compared to intermittent dosing," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "We are pleased to continue to see evidence of good tolerability and no Grade 3 rash with XL647, and believe that a daily dosing strategy may have the potential to further enhance the anti-tumor activity in NSCLC."

The most common treatment-related adverse events (AEs) were Grade 1 and 2 diarrhea and dysgeusia, fatigue, rash, and clinically asymptomatic QTc prolongation. In phase 1, a total of ten serious AEs were reported in six patients; of these events, two were considered possibly or probably related to XL647. These two drug-related events of Grade 3 pneumonitis and Grade 4 myocardial infarction occurred in the same patient. The cohort was expanded, and no further dose-limiting toxicities (DLTs) w
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
2. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
3. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
4. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
5. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
6. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
7. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
8. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
9. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
10. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
11. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Ga. , July 6, 2015  EndoChoice Holdings, ... its second quarter 2015 financial results on Thursday, August ... EndoChoice will hold a conference call on Thursday, August ... results. The dial-in numbers are (866) 807-9684 for domestic ... webcast of the conference call will be available on ...
(Date:7/6/2015)... July 6, 2015  Nitin Tandon, M.D., UTHealth ... Memorial Hermann Mischer Neuroscience Institute at ... RNS® System technology into the skull of a ... of seizures – the first time this procedure ... "Epilepsy is a neurological condition that affects ...
(Date:7/6/2015)... 6, 2015 Mauna Kea ... multidisciplinary confocal laser endomicroscopy platform, announced today it ... Ministry of Health, Labor and Welfare (MHLW) ... the AQ-Flex 19 miniprobe.   Used ... miniprobe is comprised of a fiber-optic microscope that ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 2Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 3Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 4Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 2Mauna Kea Technologies Receives Regulatory Approval for the AQ-Flex 19 Miniprobe in Japan 3
... REDWOOD CITY, Calif., Feb. 6, 2012 Cardica, Inc. (Nasdaq: ... fiscal second quarter ended December 31, 2011. Cardica,s management will ... to discuss the financial results and provide an update on ... progress on bringing our MicroCutter product line to the marketplace," ...
... 2012  A recent discovery by Van Andel Research Institute ... proposed drug therapies for glioblastoma – the most common ... The study, published in January in the ... , investigated glioblastoma models characterized by cell signaling activation ...
Cached Medicine Technology:Cardica Announces Fiscal 2012 Second Quarter Financial Results 2Cardica Announces Fiscal 2012 Second Quarter Financial Results 3Cardica Announces Fiscal 2012 Second Quarter Financial Results 4Cardica Announces Fiscal 2012 Second Quarter Financial Results 5Cardica Announces Fiscal 2012 Second Quarter Financial Results 6Discovery Predicts Patient Sensitivity to Important Drug Target in Deadly Brain Cancer 2
(Date:7/6/2015)... ... 2015 , ... On June 22, 2015, Fox News in a report titled “ Female Hair Loss Needs ... 35 a quarter of all women in the U.S. will suffer from thinning hair or ... rarely discussed. One woman, a former beauty queen, who was interviewed for the report began ...
(Date:7/6/2015)... ... July 06, 2015 , ... Acara Partners, a leading business ... of its complimentary educational webinar series for the summer of 2015. ... for their clients through targeted marketing, sales, digital communications, branding and business development ...
(Date:7/6/2015)... ... July 06, 2015 , ... Hundreds ... for aesthetic reasons, which is why liposuction regularly ranks among the top five ... fat reduction has become more than a way to slim down a silhouette ...
(Date:7/6/2015)... , ... July 06, 2015 , ... Olive Fertility Centre ... UBC 2014-2015 Post Graduate Teaching Award on behalf of the department of Family Practice. ... very exciting field to be practicing in. The technology is changing so rapidly and ...
(Date:7/6/2015)... ... July 06, 2015 , ... doTERRA, the leading global essential oils company, is ... recently, Jowers held the position as Director of the Hinckley Institute at the University ... building the institute, Jowers states that he was ready for a new challenge, and ...
Breaking Medicine News(10 mins):Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3Health News:Olive Fertility Centre Physician Honoured for Teaching 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 2Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 3Health News:doTERRA Welcomes Kirk Jowers to Its Executive Team 4
... PHOENIX, June 8 Summer can be a fun time of year, ... Plan Arizona encourages area seniors to take extra precautions this season with ... Prevent sunburn. Applying sunscreen ... prior to going out, everyday. Reapply every two to four hours, more ...
... S.C. and Rochester ... Pilot Projects Underway, According to New Reports from HealthLeaders-InterStudy ... leading provider of managed care market intelligence, reports that medical ... scrutiny as stakeholders determine whether such programs can save money ...
... cancer treatment that inhibits nicotine receptors was shown to double ... The results of the early phase animal model study were ... Journal of Respiratory and Critical Care Medicine . ... only with the tendency to smoke, but with susceptibility to ...
... conducted under the direction of Melinda Sothern, PhD, Professor ... Sciences Center New Orleans School of Public Health, showing ... as seven years old will be presented at the ... New Orleans. Dr. Sothern,s group is the first to ...
... , children and teens require different treatment, according to ... British Journal of Sports Medicine ,s new guidelines ... and activities restricted until fully healed. These restrictions include ... to school, and no cognitive activity. The new ...
... American Diabetes Association Scientific Sessions - , , ... Sansum Diabetes Research Institute scientists have demonstrated for the ... can safely and effectively maintain desired blood glucose levels ... study results will be presented today in a late-breaking ...
Cached Medicine News:Health News:SCAN Health Plan Arizona Encourages Sun Smarts and Plenty of Water for Seniors This Summer 2Health News:Medical Home Pilot Initiatives Continue to Expand Nationwide 2Health News:Medical Home Pilot Initiatives Continue to Expand Nationwide 3Health News:Defeating nicotine's double role in lung cancer 2Health News:Defeating nicotine's double role in lung cancer 3Health News:LSUHSC researchers first to document early signs for diabetes in kids as young as 7 2Health News:LSUHSC researchers first to document early signs for diabetes in kids as young as 7 3Health News:Concussion experts: For kids -- no sports, no schoolwork, no text messages 2Health News:Automated 'Artificial Pancreas' Controls Blood Glucose Levels in Diabetes Patients for First Time 2Health News:Automated 'Artificial Pancreas' Controls Blood Glucose Levels in Diabetes Patients for First Time 3
Wire mesh braided design with a platinum core....
... Finnpipette Focus multichannel pipettes ... of reagents into microplates, ... 0.1-10 l volumes. The ... Finnpipette Focus multichannels, combined ...
... The Finnpipette Digital Multichannel, ... even lighter work of routine ... all these advanced features: Soft-touch ... micro volume pipetting (0.5-10ul models), ...
... and Benefits: 1-12channel pipette This ... product number, created to easily ... showing no availability yet, please ... number (Z37,173-4) or contact customer ...
Medicine Products: